

Barcelona, December 22nd 2017

SIGNIFICANT EVENT

Almirall: distribution agreement with AstraZeneca for CRESTOR[®] and PROVISACOR[®] (rosuvastatin) in Spain

Almirall, S.A. ("Almirall"), pursuant to article 228 of the restated text of the Securities Market Act approved by the Royal Legislative Decree 4/2015, of 23 October and related provisions, hereby announces:

The execution of a license and supply agreement with AstraZeneca for Crestor[®] and Provisacor[®] (rosuvastatin). Crestor[®] and Provisacor[®] are products indicated as cholesterol-lowering treatments. These products are experiencing a generic impact.

This license agreement grants Almirall exclusive rights to commercialize Crestor[®] and Provisacor[®] in Spain.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com